Yutaka Oji

Yutaka Oji

Auto-generated profile, based on publicly available information

Yutaka Oji

Neurology, Juntendo Univerity Faculty of Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2020 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
SUShinichi Ueno
Shinichi Ueno
THTaku Hatano
Taku Hatano
AOAyami Okuzumi
Ayami Okuzumi
SSShinji Saiki
Shinji Saiki
YOYutaka Oji
Yutaka Oji
NHNobutaka Hattori
Nobutaka Hattori
Objective: To investigate the oxidized albumin ratio, which is the redox ratio of human nonmercaptalbumin (HNA) to serum albumin (%HNA), as a biomarker in idiopathic Parkinson’s disease (iPD) and related neurodegenerative disorders.Methods: This prospective study enrolled 216 iPD patients, 15 patients with autosomal recessive familial PD due to parkin mutations (PARK2), 30 multiple system atrophy (MSA) patients, 32 progressive nuclear palsy (PSP) patients, and 143 healthy controls. HNA was analyzed using modified high‐performance liquid chromatography and was evaluated alongside other parameters.Results: iPD and PARK2 patients had a higher %HNA than controls (iPD vs. controls: odds ratio (OR) 1.325, P < 0.001; PARK2 vs. controls: OR 1.712, P < 0.001). Even iPD patients at an early Hoehn & Yahr stage (I and II) showed a higher %HNA than controls. iPD patients had a higher %HNA than MSA and PSP patients (iPD vs. MSA: OR 1.249, P < 0.001, iPD vs. PSP: OR 1.288, P < 0.05). When discriminating iPD patients from controls, %HNA corrected by age achieved an AUC of 0.750; when discriminating iPD patients from MSA and PSP patients, an AUC of 0.747 was achieved. Furthermore, uric acid, an antioxidant compound, was decreased in iPD patients, similar to the change in %HNA.Interpretation: %HNA was significantly increased in iPD and PARK2 patients compared with controls, regardless of disease course and severity. Oxidative stress might be increased from the early stages of iPD and PARK2 and play an important role in their pathomechanisms.

22 December 2013 in Case Reports in Neurological Medicine
Verified
Journal Article
Open access
PDF file
KNKenya Nishioka
Kenya Nishioka
RTRyota Tanaka
Ryota Tanaka
STSatoshi Tsutsumi
Satoshi Tsutsumi
HSHideki Shimura
Hideki Shimura
YOYutaka Oji
Yutaka Oji
TUTakao Urabe
Takao Urabe
Background. Longitudinally extensive transverse myelitis (LETM) is characterized by spinal cord inflammation extending vertically through three or more vertebral segments. The widespread use of MRI revealed LETM more frequency than ever. We report the case of a patient with pathologically confirmed small-cell lung carcinoma metastasis into the spinal cord presenting as LETM.Case Presentation. A 74-year-old man developed rapidly progressive sensorimotor disturbance and vesicorectal dysfunction. T2-weighted magnetic resonance imaging of the spine revealed LETM at the level of from T3 to conus medullaris; gadolinium enhancement showed concurrent tumor in the thoracic spinal cord from T10 to T11. Systemic survey identified a nodular mass in the lung that was verified as small-cell carcinoma. Following initial failed treatment by high-dose steroid, the patient underwent an emergent microsurgical tumor resection. Histological examination was identical with the lung carcinoma. The patient died of tumor progression at the 47th day after admission. At autopsy, only changes of edema were found in the gray matter of the cord, while tumor cells were not noted in it.Conclusion. Metastasis may rarely present symptoms of LETM. Prompt identification of underlying etiology by contrast examination and systemic survey is crucial for the patient assumed as LETM.

11 February 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
THTaku Hatano
Taku Hatano
GOGenko Oyama
Genko Oyama
YSYasushi Shimo
Yasushi Shimo
KOKotaro Ogaki
Kotaro Ogaki
NNNoriko Nishikawa
Noriko Nishikawa
NHNobutaka Hattori
Nobutaka Hattori
Introduction Chronic constipation worsens the quality of life (QOL) of patients with Parkinson’s disease (PD). Elobixibat, an ileal bile acid transporter inhibitor, is a useful laxative, but its effect on chronic constipation in patients with PD remains unclear. Therefore, we designed a placebo-controlled, randomised, double-blind study to investigate the efficacy and safety of elobixibat in patients with PD with chronic constipation. Methods and analysis The study will consist of 2-week observation and 4-week treatment periods. Patients with clinically established PD will record the status of spontaneous bowel movements and use of rescue medications/concomitant medications in a Bowel Movement Diary from the start of the observation period at visit 1 (week −2). At visit 2 (week 0), patients will be assessed for final registration based on the diary records and physical examinations, and allocated to either the elobixibat or placebo group. Daily intake of the investigational drug will be recorded in the diary. Patients will undergo laboratory tests and answer constipation-related, PD-related and QOL-related questionnaires at visits 2 and 4 (week 4). Subjective symptoms and objective findings will be collected at visits 2, 3 (week 2) and 4. Since patients’ motor function might be improved by treatment of constipation, the use of dopamine preparations will also be monitored. Bowel movement data and other parameters will be compared between groups. Safety information will be collected as adverse events, specifically focusing on those occurring in association with study conduct. Ethics and dissemination This study will be conducted in accordance with the Helsinki Declaration, the Clinical Trials Act of the Japan Ministry of Health, Labour and Welfare, and related laws and regulations. The study was approved by the Juntendo University Certified Review Board. The results will be disseminated through an online study registry (Japan Registry of Clinical Trials), presented at scientific conferences, and published in medical journals. Trial registration number JPRN-jRCTs031200172; Pre-results.

23 October 2026 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
GOGenko Oyama
Genko Oyama
YIYoshinori Ishida
Yoshinori Ishida
YTYoshio Tsuboi
Yoshio Tsuboi
SFShinsuke Fujioka
Shinsuke Fujioka
TTTaiji Tsunemi
Taiji Tsunemi
NHNobutaka Hattori
Nobutaka Hattori